

# Allograft Nerve Repair

DRAFT



Medicaid Medical Coverage Policy

Original Effective Date: 10/07/2025

Effective Date: xx/xx/xxxx

Review Date: 10/07/2025

Policy Number: HUM-LA-2267-000

Line of Business: Medicaid

State(s): LA

## Table of Contents

Description

Coverage Limitations

References

Coverage Determination

Coding Information

Change Summary

### Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

## Description

Allograft nerve repair uses processed nerves from donors or cadavers to aid surgeons in repairing nerve injuries that require gap bridging. These processed nerve allografts (PNA) are prepared by various methods (eg, freezing, irradiation, detergents) to remove living cells. The current gold standard for nerve repair is autologous nerve graft, where nerves are harvested from the same individuals that will undergo the repair. Surgeons harvest grafts from nonessential nerves such as sural, antebrachial cutaneous and superficial radial nerves. PNA may be used as an alternative to autologous nerve grafts, which avoids donor morbidity associated with autologous nerve repair. Currently the only PNA commercially available in the United States is Avance Nerve Graft intended for the surgical repair of peripheral nerve gaps.

## Coverage Determination

Humana members may be eligible under the Plan for allograft nerve repair (64912) for the following indications:

- Primary direct nerve repair is not possible<sup>2,4</sup>; AND
- Repair of peripheral nerve gaps less than or equal to 70 mm<sup>4,8</sup>

## Coverage Limitations

Humana members may NOT be eligible under the Plan for allograft nerve repair for any indications other than those listed above.

A review of the current medical literature shows that the evidence is insufficient to determine that Allograft nerve repair is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

## Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

<u>CPT® Code(s)</u>	<u>Description</u>	<u>Comments</u>
<u>64912</u>	<u>Nerve repair; with nerve allograft, each nerve, first strand (cable)</u>	-
<u>CPT® Category III Code(s)</u>	<u>Description</u>	<u>Comments</u>
<u>No code(s) identified</u>		
<u>HCPCS Code(s)</u>	<u>Description</u>	<u>Comments</u>
<u>No code(s) identified</u>		

## References

1. American Association of Hand Surgery (AAHS). 2025 Nerve allograft statement. <https://handsurgery.org>. Published July 2025.
2. ClinicalKey. Frost C, Rosson, GD. Nerve injury and repair. In Cameron AM, Cameron JL. *Current Surgical Therapy*. 14<sup>th</sup> ed. Elsevier; 2023:937-945. <https://clinicalkey.com>.
3. ClinicalKey. Isaacs J, Nydick JA, et al. A multicenter prospective randomized comparison of conduits versus decellularized nerve allograft for digital nerve repairs. *J Hand Surg*. 2023;48(9):904-913. <https://clinicalkey.com>.

4. ClinicalKey. Krauss EM, Weber RV, Mackinnon, SE. Nerve injury, repair, and reconstruction. In: Farhadieh RD, Bulstrode NW, et al. Plastic Surgery: Principles and Practice. Elsevier; 2022:803-825. <https://clinicalkey.com>.
5. ClinicalKey. Netscher D, Agrawal N, Fiore NA. Hand surgery. In: Townsend JR CM, Beauchamp RD, et al. Sabiston Textbook of Surgery. 21<sup>st</sup> ed. Elsevier; 2022:1945-1998.e1. <https://clinicalkey.com>.
6. ECRI Institute. Clinical Evidence Assessment. Processed nerve allografts for repairing peripheral nerve gap injuries. <https://home.ecri.org>. Published July 15, 2025.
7. Hayes, Inc. Health Technology Assessment. Processed nerve allografts with the Avance Nerve Graft (Axogen Corporation) for peripheral nerve discontinuities. <https://evidence.hayesinc.com>. Published March 2, 2020. Updated May 11, 2023.
8. Lans J, Eberlin KR, Evans PJ, Mercer DM, Greeber JA, Styron JF. A systematic review and meta-analysis of nerve gap repair: comparative effectiveness of allografts, autografts, and conduits. *Plast Reconstr Surg*. 2023;151(1):814e-827e.

## Change Summary

10/07/2025 New Policy.